SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.11-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (3802)5/15/2001 11:15:15 PM
From: Biomaven  Read Replies (2) of 52153
 
The new NIH guidelines for cholesterol should mostly benefit the statin purveyors, which are currently all pharmas. However, one biotech, KOSP, should benefit. Currently if you want to raise HDL, then KOSP's drug is the only game in town. This will likely change in a few years as all the pharmas are charging very hard after an effective drug, but meantime KOSP should benefit. Their new drug, a combined lovastatin (generic version) and niacin should also do nicely once it is approved, particularly in a cost-conscious environment.

Here's a CNN write-up of the new guidlines:

cnn.com

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News